4D Molecular Therapeutics (FDMT)

• Market cap: $216M
• 1 day: 1.97%
• 5 days: -3.31%
• 1 month: -20.58%
• 3 months: -45.57%
• 6 months: -72.66%
• Year to date: -19.90%
• 1 year: -73.75%
• 5 years: -88.47%
• 10 years: -88.47%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Employees: 201

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

38% more call options, than puts

Call options by funds: $1.66M | Put options by funds: $1.21M

27% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 44

2.76% less ownership

Funds ownership: 114.4% [Q2] → 111.64% (-2.76%) [Q3]

3% less funds holding

Funds holding: 143 [Q2] → 139 (-4) [Q3]

12% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 25

49% less capital invested

Capital invested by funds: $1.24B [Q2] → $628M (-$614M) [Q3]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6 28% upside
• Avg. target: $32 589% upside
• High target: $46 885% upside

6 analyst ratings

• positive: 5 83%
• neutral: 0 0%
• negative: 1 17%

Morgan Stanley Judah Frommer 33% 1-year accuracy 3 / 9 met price target	28% upside $6	Underweight Maintained	13 Jan 2025
Leerink Partners Mani Foroohar 24% 1-year accuracy 4 / 17 met price target	478% upside $27	Outperform Maintained	13 Jan 2025
HC Wainwright & Co. Matthew Caufield 19% 1-year accuracy 10 / 52 met price target	671% upside $36	Buy Reiterated	13 Jan 2025
B of A Securities Tazeen Ahmad 24% 1-year accuracy 7 / 29 met price target	885% upside $46	Buy Maintained	18 Dec 2024
Chardan Capital Geulah Livshits 8% 1-year accuracy 4 / 49 met price target	735% upside $39	Buy Maintained	14 Nov 2024